Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity
We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 1995-08, Vol.38 (17), p.3391-3397 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3397 |
---|---|
container_issue | 17 |
container_start_page | 3391 |
container_title | Journal of medicinal chemistry |
container_volume | 38 |
creator | Azuma, Atsushi Hanaoka, Kenji Kurihara, Atsushi Kobayashi, Tomowo Miyauchi, Seiji Kamo, Naoki Tanaka, Motohiro Sasaki, Takuma Matsuda, Akira |
description | We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC. |
doi_str_mv | 10.1021/jm00017a023 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77463046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16961104</sourcerecordid><originalsourceid>FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</originalsourceid><addsrcrecordid>eNqFks1v0zAYxgMCjTI4ceCE5BMDgYvt2HHKrcpYmTQK0gbiZr1xHOEuiYvtwPLf46rT2AGxg-WP5-fn8Wu9WfaMkjkljL7b9IQQKoGw_H42o4IRzEvCH2QzQhjDrGD5o-xxCJuE5ZTlB9mBLAQpFmx27_l61J1xwTYmIBgatN_H3X6OKKdzVP0wvdXQofMIte1snJBrEaC1-Y2WQ7Rx7J1Hf33eInaEK1xNMDiclo1xVxOmeF6bCHN8jMEnn6RtzRBdO_rEhanTU0zXB4NeVevjZfUa2QEtu0vodmefTGPH_j06cb6HaN2we8IdMd7W_81IEbuCT2O4VcZSR_srlfgke9hCF8zT6_kw-3ry4aL6iM8-r06r5RkGLmjEpQSpuQYtOG8bAYJL0VDa1rwohRSLsm0YYSUzGkzJmSHUmLaFullwAjkR-WH2cu-79e7naEJUvQ3adB0Mxo1BScmLnKRxF0iLRUEp4Ql8swe1dyF406qttz34SVGidv2ibvVLol9c2451b5ob9rpBko73ug3RXN3I4C9VIXMp1MWXcyW_rUq5yqX6nvijPQ86qI0b_ZB-75_JfwDQCtXl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16961104</pqid></control><display><type>article</type><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><source>MEDLINE</source><source>ACS Publications</source><creator>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</creator><creatorcontrib>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</creatorcontrib><description>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00017a023</identifier><identifier>PMID: 7650692</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Adenocarcinoma - pathology ; Animals ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; Cell Division - drug effects ; Colonic Neoplasms - pathology ; Cytarabine - analogs & derivatives ; Cytarabine - chemical synthesis ; Cytarabine - chemistry ; Cytarabine - pharmacology ; Drug Stability ; Female ; Humans ; Hydrogen-Ion Concentration ; Leukemia P388 - pathology ; Mice ; Mice, Inbred DBA ; Ribonucleosides - chemical synthesis ; Ribonucleosides - chemistry ; Ribonucleosides - pharmacology ; Spectrum Analysis ; Tumor Cells, Cultured</subject><ispartof>Journal of medicinal chemistry, 1995-08, Vol.38 (17), p.3391-3397</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00017a023$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00017a023$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7650692$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azuma, Atsushi</creatorcontrib><creatorcontrib>Hanaoka, Kenji</creatorcontrib><creatorcontrib>Kurihara, Atsushi</creatorcontrib><creatorcontrib>Kobayashi, Tomowo</creatorcontrib><creatorcontrib>Miyauchi, Seiji</creatorcontrib><creatorcontrib>Kamo, Naoki</creatorcontrib><creatorcontrib>Tanaka, Motohiro</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Matsuda, Akira</creatorcontrib><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</description><subject>Adenocarcinoma - pathology</subject><subject>Animals</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Cell Division - drug effects</subject><subject>Colonic Neoplasms - pathology</subject><subject>Cytarabine - analogs & derivatives</subject><subject>Cytarabine - chemical synthesis</subject><subject>Cytarabine - chemistry</subject><subject>Cytarabine - pharmacology</subject><subject>Drug Stability</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Leukemia P388 - pathology</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Ribonucleosides - chemical synthesis</subject><subject>Ribonucleosides - chemistry</subject><subject>Ribonucleosides - pharmacology</subject><subject>Spectrum Analysis</subject><subject>Tumor Cells, Cultured</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1v0zAYxgMCjTI4ceCE5BMDgYvt2HHKrcpYmTQK0gbiZr1xHOEuiYvtwPLf46rT2AGxg-WP5-fn8Wu9WfaMkjkljL7b9IQQKoGw_H42o4IRzEvCH2QzQhjDrGD5o-xxCJuE5ZTlB9mBLAQpFmx27_l61J1xwTYmIBgatN_H3X6OKKdzVP0wvdXQofMIte1snJBrEaC1-Y2WQ7Rx7J1Hf33eInaEK1xNMDiclo1xVxOmeF6bCHN8jMEnn6RtzRBdO_rEhanTU0zXB4NeVevjZfUa2QEtu0vodmefTGPH_j06cb6HaN2we8IdMd7W_81IEbuCT2O4VcZSR_srlfgke9hCF8zT6_kw-3ry4aL6iM8-r06r5RkGLmjEpQSpuQYtOG8bAYJL0VDa1rwohRSLsm0YYSUzGkzJmSHUmLaFullwAjkR-WH2cu-79e7naEJUvQ3adB0Mxo1BScmLnKRxF0iLRUEp4Ql8swe1dyF406qttz34SVGidv2ibvVLol9c2451b5ob9rpBko73ug3RXN3I4C9VIXMp1MWXcyW_rUq5yqX6nvijPQ86qI0b_ZB-75_JfwDQCtXl</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Azuma, Atsushi</creator><creator>Hanaoka, Kenji</creator><creator>Kurihara, Atsushi</creator><creator>Kobayashi, Tomowo</creator><creator>Miyauchi, Seiji</creator><creator>Kamo, Naoki</creator><creator>Tanaka, Motohiro</creator><creator>Sasaki, Takuma</creator><creator>Matsuda, Akira</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</title><author>Azuma, Atsushi ; Hanaoka, Kenji ; Kurihara, Atsushi ; Kobayashi, Tomowo ; Miyauchi, Seiji ; Kamo, Naoki ; Tanaka, Motohiro ; Sasaki, Takuma ; Matsuda, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a451t-87a7c4cac544fd5a5475d11fb46857598fd20282ecae842e01eeffabd940a3053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Animals</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Cell Division - drug effects</topic><topic>Colonic Neoplasms - pathology</topic><topic>Cytarabine - analogs & derivatives</topic><topic>Cytarabine - chemical synthesis</topic><topic>Cytarabine - chemistry</topic><topic>Cytarabine - pharmacology</topic><topic>Drug Stability</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Leukemia P388 - pathology</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Ribonucleosides - chemical synthesis</topic><topic>Ribonucleosides - chemistry</topic><topic>Ribonucleosides - pharmacology</topic><topic>Spectrum Analysis</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azuma, Atsushi</creatorcontrib><creatorcontrib>Hanaoka, Kenji</creatorcontrib><creatorcontrib>Kurihara, Atsushi</creatorcontrib><creatorcontrib>Kobayashi, Tomowo</creatorcontrib><creatorcontrib>Miyauchi, Seiji</creatorcontrib><creatorcontrib>Kamo, Naoki</creatorcontrib><creatorcontrib>Tanaka, Motohiro</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Matsuda, Akira</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azuma, Atsushi</au><au>Hanaoka, Kenji</au><au>Kurihara, Atsushi</au><au>Kobayashi, Tomowo</au><au>Miyauchi, Seiji</au><au>Kamo, Naoki</au><au>Tanaka, Motohiro</au><au>Sasaki, Takuma</au><au>Matsuda, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>38</volume><issue>17</issue><spage>3391</spage><epage>3397</epage><pages>3391-3397</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>7650692</pmid><doi>10.1021/jm00017a023</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1995-08, Vol.38 (17), p.3391-3397 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_77463046 |
source | MEDLINE; ACS Publications |
subjects | Adenocarcinoma - pathology Animals Antineoplastic Agents - chemical synthesis Antineoplastic Agents - pharmacology Cell Division - drug effects Colonic Neoplasms - pathology Cytarabine - analogs & derivatives Cytarabine - chemical synthesis Cytarabine - chemistry Cytarabine - pharmacology Drug Stability Female Humans Hydrogen-Ion Concentration Leukemia P388 - pathology Mice Mice, Inbred DBA Ribonucleosides - chemical synthesis Ribonucleosides - chemistry Ribonucleosides - pharmacology Spectrum Analysis Tumor Cells, Cultured |
title | Nucleosides and Nucleotides. 141. Chemical Stability of a New Antitumor Nucleoside, 2'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine (CNDAC) in Alkaline Medium: Formation of 2'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine (CNDC) and Its Antitumor Activity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T01%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nucleosides%20and%20Nucleotides.%20141.%20Chemical%20Stability%20of%20a%20New%20Antitumor%20Nucleoside,%202'-C-Cyano-2'-deoxy-1-.beta.-D-arabino-pentofuranosylcytosine%20(CNDAC)%20in%20Alkaline%20Medium:%20Formation%20of%202'-C-Cyano-2'-deoxy-1-.beta.-D-ribo-pentofuranosylcytosine%20(CNDC)%20and%20Its%20Antitumor%20Activity&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Azuma,%20Atsushi&rft.date=1995-08-01&rft.volume=38&rft.issue=17&rft.spage=3391&rft.epage=3397&rft.pages=3391-3397&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm00017a023&rft_dat=%3Cproquest_cross%3E16961104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16961104&rft_id=info:pmid/7650692&rfr_iscdi=true |